Chimera Biotec: Ultra sensitive bioanalysis & beyond
Large-molecule sample testing support from the industry’s longest standing experts for ultra sensitive bioanalysis
Why ultra sensitivity:
While the sensitivities of classic, colorimetric ELISA (enzyme linked immunosorbent assay) are sufficient for bioanalysis in many cases, there is a growing interest in immunoassay techniques whose detection capabilities go beyond those of ELISA. The complexity and novel mechanisms of action of contemporary, biotherapeutic drugs (biologics) increasingly demand ultra sensitive detection methods for both PK sample testing as well as for endogenous or drug-related, low abundance biomarkers.
Who we are:
Pioneers in the field, Chimera Biotec has been specialized in supporting drug development programs that demand the highest bioanalytical quality since 2000. Our long standing expertise in beyond ELISA sensitivity immunoassays enables us to make the most out of any immunoassay platform and provide our customers with accurate and comprehensive scientific results.
What we do:
For more than 15 years, Chimera Biotec has specialized in supporting drug development programs with highest demands on bioanalytical quality. We develop and validate ultra sensitive immunoassays in accordance with the regulatory requirements and bioanalytical method validation guidance documents.
Based on your antibody experience on your preferred in-house immunoassay platform, we can run a technology evaluation and feasibility study across our ultra sensitive platforms. The resulting data will allow you to select the platform best-suited to support your study's bioanalytical needs.
What makes us different:
With our expert knowledge in sample dilution – based on our proprietary AnySource® technology – we can utilize sensitivity to tailor your assay towards alternate needs, such as minimal sample consumption for bioanalytical studies involving microsampling or rare matrices.
Our quality standards:
Our GLP/GCP certified laboratories deliver bioanalytical services ranging from non-regulated research processing of a few samples to the handling of thousands of samples for clinical phase-III research on time.